CNBG

Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China

Retrieved on: 
Monday, June 12, 2023
Medicine, Croma, Lidocaine, Filler (linguistics), Clinical trial, Patient, CNBG, Growth, Safety, Pharmaceutical industry, Fine chemical, Sinopharm (company)

VIENNA, June 12, 2023 /PRNewswire/ -- Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China.

Key Points: 
  • VIENNA, June 12, 2023 /PRNewswire/ -- Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China.
  • Lanhzou Biotechnique Development is an affiliate of China National Biotech Group (CNBG), a subsidiary of Sinopharm, with whom Croma-Pharma has established a joint venture in China.
  • hyaluronic acid dermal fillers, and Lanzhou Biotechnique Development's botulinum toxin in China and Hong Kong, covering synergistic medical aesthetic indications.
  • The Princess® HA filler range comprises Princess® Rich (non-lidocaine), Princess® Filler, Princess® Volume (lidocaine and non-lidocaine types) and Princess® Volume Plus (lidocaine).

Charles Huang Foundation Makes Record-Breaking US$40 Million Donation to His Alma Mater, Wuhan University

Retrieved on: 
Tuesday, November 30, 2021
Innova, World Health Organization, CNBG, Doctor of Philosophy, Securities Industry Automation Corporation, School, Management science, CA, California State Assembly, Student, ASOCS, University, University of Strathclyde, SE, Left, Research, Tsinghua University School of Economics and Management, Infection, BNP, MBA, Education, Solution, Vaccine, Goal, Growth, ATL, Roma Education Fund, Foundation, BNP Paribas, Business school, TMT, Crédit Lyonnais, Entrepreneurship, HSBC, COVID-19, CHF, Innovation, Pharmaceutical industry, Creative industries, Management

This philanthropic gift is the single-largest personal donation ever received by Wuhan University.

Key Points: 
  • This philanthropic gift is the single-largest personal donation ever received by Wuhan University.
  • Together with the US$70 million landmark grant given by CHF to the University of Strathclyde in the UK in September, Dr Huang has donated a total of US$110 million to his two alma maters through his philanthropic foundation this year.
  • Dr Charles Huang, Founder and Chairman of Charles Huang Foundation (Right), and Professor Dou Xiankang, President of Wuhan University (Left), jointly signed the unprecedented grant agreement
    The donation was formally made at a virtual signing ceremony held between Wuhan University campus in China and the Foundation headquarters in Pasadena, California, earlier today.
  • "As his alma mater, we are very proud that Wuhan University helped to cultivate such a global visionary entrepreneur like Dr Huang.

Croma Establishes New Joint Venture in China

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, Cosmetics, Retail, Other Health, Drugs, Toxins, Botulinum toxin, Botulism, Neurotoxins, Lanzhou, Croma, 2-hydroxymuconate tautomerase, Croma-Pharma GmbH - leading experts in Hyaluronic Acid, CNBG

CNBG and Croma entered a far reaching, long-term cooperation combining each partners assets in a newly founded Joint Venture company to market Cromas aesthetic products in China and Hong Kong.

Key Points: 
  • CNBG and Croma entered a far reaching, long-term cooperation combining each partners assets in a newly founded Joint Venture company to market Cromas aesthetic products in China and Hong Kong.
  • The joint company aims to become a comprehensive supplier of minimally invasive aesthetic products in China, making effective use of the existing field force of Lanzhou.
  • Xiangrong Li, Vice-president of CNBG said: CNBG, via its affiliate Lanzhou, has been very successful for years with its botulinum toxin in China.
  • Andreas Prinz, CCO and Co-Owner of Croma: "Croma incorporates more than 40 years of experience in R&D of viscoelastic products.